R&D strategy

Ipsen's ambitions in Research & Development are spearheaded by two technological platforms focused on peptides and toxins, a strong commitment to translational research, a robust partnership policy and a promising pipeline.

The success of Ipsen’s R&D is based on five key closely interlinked objectives.
 
Patient focus
 
Ipsen’s mission, “innovation for patient care”, highlights the Group’s commitment to focus on patients and unmet medical needs and to provide innovative therapeutic solutions. Focusing on patients is critical to determine unmet medical needs and identify both the pathophysiological and disease molecular mechanisms and biological targets that should be developed. This approach is fundamental both in clinical development phases and to bring innovative molecules to the market.

Focus and align priorities on the Franchise strategy

The Franchises determine medical needs and contribute to specifying patient populations which most require new and differentiated treatments. Research then defines which molecular targets should be stimulated or inhibited to satisfy the medical need. This collaboration fosters the development of competitive molecules. This highly focused approach concentrates efforts on unmet medical needs, while optimizing the allocation of resources.

Scientific and medical excellence

Focused on peptides and toxins, Ipsen’s internal R&D is concentrating and developing its expertise on these two platforms with the objective of increasing its understanding of both basic sciences and clinical aspects. Ipsen has entered into agreements with highly specialized companies and is strengthening its partnership policy through agreements with major research institutes and medical centers of excellence, on a global scale.

Speed of execution across the value chain

During preclinical and clinical development, the early designation of therapeutic targets and markers allows us to better define the potential value of molecules, accelerate the development process as well as the construction of the product dossiers which are submitted to regulatory bodies for market authorization.

An open and collaborative project-centric innovation model

The alignment of priorities of the Franchises and the implementation of project teams – which bring together a broad range of competencies focused on shared objectives – are the pillars of Ipsen’s collaborative innovation model. The Group’s innovation model, which fosters the development of partnerships with major research institutes (Salk Institute, US) and centers of excellence (Institut Gustave Roussy, France; Massachusetts General Hospital, US, etc.), allows Ipsen to leverage the breadth of its strengths. Compared with peers of comparable size and positioning, Ipsen is one of the pharmaceutical companies with the most projects in phase III.